Key terms
About SAGE
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SAGE news
Yesterday
4:55am ET
Sage Therapeutics management to meet with Piper Sandler
Mar 27
9:50pm ET
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Mar 26
8:42am ET
SAGE Therapeutics Board Member Announces Retirement
Mar 26
6:12am ET
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics, Inc. (APGE), SAGE Therapeutics (SAGE)
Mar 11
6:50am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Janux Therapeutics Inc (JANX) and SAGE Therapeutics (SAGE)
Feb 23
11:55am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 23
11:00am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 19
12:51am ET
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), SAGE Therapeutics (SAGE) and IQVIA Holdings (IQV)
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 16
8:30am ET
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and EyePoint Pharmaceuticals (EYPT)
Feb 15
10:05am ET
SAGE Therapeutics’ Zurzuvae Launch: A Promising Start Amid Operational Cautions
Feb 15
10:01am ET
Sage Therapeutics price target raised to $28 from $25 at H.C. Wainwright
Feb 15
8:56am ET
Sage Therapeutics price target raised to $26 from $21 at RBC Capital
Feb 15
8:38am ET
Sage Therapeutics price target raised to $25 from $23 at Oppenheimer
Feb 15
8:03am ET
Analysts Conflicted on These Healthcare Names: Genmab (GMAB), cbdMD (YCBD) and SAGE Therapeutics (SAGE)
Feb 15
7:20am ET
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), SAGE Therapeutics (SAGE) and Illumina (ILMN)
Feb 15
7:02am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (SYK), SAGE Therapeutics (SAGE) and Healthcare Services (HCSG)
Feb 15
6:11am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (THC), SAGE Therapeutics (SAGE) and American Well (AMWL)
Feb 15
1:02am ET
Bad News for SAGE Therapeutics, Inc. (US) Stock: This New Risk Has Been Added
Feb 14
7:25pm ET
Buy Rating for SAGE Therapeutics Amid Strong Early Demand for Zurzuvae and Solid Financial Position
Feb 14
5:53pm ET
Sage Therapeutics price target raised to $28 from $27 at Goldman Sachs
Feb 14
6:33am ET
Sage Therapeutics expects cash available will support its operations into 2026
Feb 14
6:32am ET
Sage Therapeutics reports Q4 EPS (55c), consensus ($1.28)
Feb 13
4:31pm ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SAGE Therapeutics (SAGE) and Rocket Pharmaceuticals (RCKT)
Feb 09
10:46am ET
SAGE Therapeutics: Hold Rating with Modest Zurzuvae Sales and Shifted Focus to PPD-Only Investment Thesis
Feb 09
10:38am ET
Sage Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
Jan 25
4:24am ET
SAGE Therapeutics Secures New Cambridge Headquarters Lease
Jan 22
7:29am ET
Sage Therapeutics price target raised to $22 from $20 at Truist
Jan 19
7:16am ET
Sage Therapeutics price target raised to $34 from $24 at Scotiabank
Jan 17
7:52am ET
Sage Therapeutics price target raised to $30 from $26 at BofA
Jan 11
8:01am ET
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), SAGE Therapeutics (SAGE) and Globus Medical (GMED)
No recent news articles are available for SAGE
No recent press releases are available for SAGE
SAGE Financials
Key terms
Ad Feedback
SAGE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SAGE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range